Rasagiline Mesylate

CAS No. 161735-79-1

Rasagiline Mesylate( —— )

Catalog No. M12364 CAS No. 161735-79-1

Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 36 In Stock
50MG 43 In Stock
100MG 67 In Stock
200MG 90 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rasagiline Mesylate
  • Note
    Research use only, not for human use.
  • Brief Description
    Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
  • Description
    Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.(In Vitro):Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.(In Vivo):Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.
  • In Vitro
    Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.Cell Viability Assay Cell Line:Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG Concentration:0.25 nM Incubation Time:96 hours Result:Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.
  • In Vivo
    Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy. Animal Model:(PLP)-α-synuclein transgenic mice over 6 months of age Dosage:Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.) Administration:Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment). Result:Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    MAO
  • Recptor
    MAO-A| MAO-B
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    161735-79-1
  • Formula Weight
    267.34
  • Molecular Formula
    C13H17NO3S
  • Purity
    >98% (HPLC)
  • Solubility
    Soluble in water
  • SMILES
    CS(=O)(=O)O.C#CCN[C@@H]1CCC2=CC=CC=C12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Youdim MB, et al. Br J Pharmacol, 2001, 132(2), 500-506.
molnova catalog
related products
  • Milacemide

    Milacemide is a glycine prodrug and MAO-B inhibitor. Milacemide has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.

  • FCE 28073

    FCE 28073 is a Monoamine oxidase B inibitor with IC50 of 0.45 uM.

  • BW-1370U87

    BW-1370U87 is a reversible competitive monoamine oxidase-A inhibitor for the study of depression and other CNS disorders.